Cita APA

Slamon, D. J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., . . . Fasching, P. A. (2021). Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: Updated overall survival.

Citación estilo Chicago

Slamon, D. J., P. Neven, S. Chia, G. Jerusalem, M. De Laurentiis, S. Im, Luis de la Cruz Merino, y P. A. Fasching. Ribociclib Plus Fulvestrant for Postmenopausal Women With Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the Phase III Randomized MONALEESA-3 Trial: Updated Overall Survival. 2021.

Cita MLA

Slamon, D. J., et al. Ribociclib Plus Fulvestrant for Postmenopausal Women With Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the Phase III Randomized MONALEESA-3 Trial: Updated Overall Survival. 2021.